Keynote-045: Open-label, phase 3 study of pembrolizumab versus investigator's choice of paclitaxel, docetaxel, or vinflunine for previously treated advanced urothelial cancer Meeting Abstract
| Authors: | Quinn, D.; Bellmunt, J.; de Wit, R.; Vaughn, D. J.; Fradet, Y.; Lee, J. L.; Fong, L.; Vogelzang, N. J.; Climent, M. A.; Petrylak, D. P.; Choueiri, T. K.; Necchi, A.; Gerritsen, W.; Gurney, H.; Culine, S.; Sternberg, C. N.; Mai, Y.; Puhlmann, M.; Perini, R. F.; Bajorin, D. F. |
| Abstract Title: | Keynote-045: Open-label, phase 3 study of pembrolizumab versus investigator's choice of paclitaxel, docetaxel, or vinflunine for previously treated advanced urothelial cancer |
| Meeting Title: | Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) Annual Scientific Meeting 2017 |
| Journal Title: | Asia-Pacific Journal of Clinical Oncology |
| Volume: | 13 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2017 Jul 16-18 |
| Meeting Location: | Melbourne, Australia |
| ISSN: | 1743-7555 |
| Publisher: | Wiley Blackwell |
| Date Published: | 2017-07-01 |
| Start Page: | 35 |
| Language: | English |
| ACCESSION: | WOS:000427541700025 |
| PROVIDER: | wos |
| DOI: | 10.1111/ajco.12718 |
| Notes: | Meeting Abstract: 25 -- Source: Wos |
